Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Abstract Background While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isa...

Full description

Bibliographic Details
Main Authors: Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann, Sandra Sauer
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Cancer
Subjects:
Multiple myeloma
Stem cell mobilization
Lenalidomide
Elotuzumab
Isatuximab
Online Access:https://doi.org/10.1186/s12885-023-11507-9

Internet

https://doi.org/10.1186/s12885-023-11507-9

Similar Items